Get the latest news, insights, and market updates on JNJ (Johnson & Johnson). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500
Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks Feb 18, 2026 - $JNJ
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy? Feb 18, 2026 - $JNJ
This State Has More Millionaires Per Capita Than Any Other
There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other Feb 18, 2026 - $JNJ
Jury: Johnson & Johnson Liabile in Case Linking Baby Powder to Cancer
On Friday, a Pennsylvania state-court jury in Philadelphia ordered Johnson & Johnson (NYSE:JNJ) to pay $250,000 to the family of Gayle Emerson, finding the company liable in a case blaming its talc baby powder for her ovarian cancer. The verdict lands as the company also fights over whether jurors will hear scientific experts in the consolidated federal docket, including a New Jersey special master's recommendation that would let plaintiffs present causation testimony, a fight detailed in key ex Feb 17, 2026 - $JNJ
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj). When administered in combination with oral LAZCLUZE® (lazertinib) for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous (SC) do Feb 17, 2026 - $JNJ
Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus
Johnson & Johnson (NYSE:JNJ) was found liable by a Philadelphia jury in an ovarian cancer case linked to long term use of its talc based baby powder. The jury awarded compensatory and punitive damages to the family of a woman who died from ovarian cancer. This case is one of over 70,000 similar lawsuits consolidated in federal court, with more trials scheduled for 2026. The verdict comes as medical authorities increasingly recognize a probable cancer risk from genital talc use, and recent... Feb 16, 2026 - $JNJ
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple